Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

L. Kappos; A. Bar-Or; B.A.C. Cree; R.J. Fox; C. Giovannoni; P. Vermersch; D.L. Arnold; S. Arnould; T. Schertz; C. Wolf; E. Walstrom; F. Dahlke; L. H. Visser

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

L. Kappos, A. Bar-Or, B.A.C. Cree, R.J. Fox, C. Giovannoni, P. Vermersch, D.L. Arnold, S. Arnould, T. Schertz, C. Wolf, E. Walstrom, F. Dahlke, L. H. Visser

Research output: Contribution to journal › Article › Academic › peer-review

Original language	American English
Pages (from-to)	1263-1273
Number of pages	11
Journal	The Lancet (London)
Volume	391
Publication status	Published - 1 Jan 2018

Cite this

@article{f518a54cc5814268be8649b5e109383f,

title = "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study",

author = "L. Kappos and A. Bar-Or and B.A.C. Cree and R.J. Fox and C. Giovannoni and P. Vermersch and D.L. Arnold and S. Arnould and T. Schertz and C. Wolf and E. Walstrom and F. Dahlke and Visser, \{L. H.\}",

year = "2018",

month = jan,

day = "1",

language = "Amerikaans engels",

volume = "391",

pages = "1263--1273",

journal = "The Lancet (London)",

issn = "0140-6736",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

AU - Kappos, L.

AU - Bar-Or, A.

AU - Cree, B.A.C.

AU - Fox, R.J.

AU - Giovannoni, C.

AU - Vermersch, P.

AU - Arnold, D.L.

AU - Arnould, S.

AU - Schertz, T.

AU - Wolf, C.

AU - Walstrom, E.

AU - Dahlke, F.

AU - Visser, L. H.

PY - 2018/1/1

Y1 - 2018/1/1

M3 - Artikel

SN - 0140-6736

VL - 391

SP - 1263

EP - 1273

JO - The Lancet (London)

JF - The Lancet (London)

ER -